Purpose of this study: To evaluate the efficacy of IDE196 with crizotinib compared to standard therapies in the treatment of metastatic uveal melanoma. Determination of the ideal dose strength of IDE196 in combination with crizotinib. Further assessments of safety and tolerability and how well the body responds to IDE196 with crizotinib compared to standard treatment.
Aim of the study
Investigation of the efficacy of IDE196 with crizotinib compared to standard therapies in the treatment of metastatic uveal melanoma. Determination of the ideal dose strength of IDE196 in combination with crizotinib. Further assessments of safety and tolerability and how well the body responds to IDE196 with crizotinib compared to standard treatment.
Who can take part?
Patients with HLA-A2-negative metastatic uveal melanoma
Procedure
Your participation in this study in the treatment phase will last approximately one to two years from the time you sign this consent form. Additional telephone or clinic follow-up checks will then take place over a period of around two years.
Original study name
IDE196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy for HLA-A2-negative metastatic uveal melanoma (DAR-UM-2)
BASEC number
2023-01759
Financial support from
IDEAYA, Biosciences